How will UK screen more black men?

UK expands prostate cancer Transform trial invitations

The UK health secretary announced that thousands more Black men will be invited to take part in a prostate cancer screening study known as the Transform trial. The expansion is aimed specifically at reaching more men from Black ethnic groups, reflecting ongoing concerns that blood tests alone are not accurate enough to guide screening decisions for most men.

The announcement also underscores a difference in approach: while the trial will widen participation, the government did not move to support population-wide prostate cancer screening. That distinction matters because it signals that officials are still weighing evidence about which screening strategies reduce deaths and which may cause unnecessary harm (such as false alarms and treatment of cancers that would not have become dangerous).

What’s likely to be changing

• More trial invitations for Black men, likely to improve the evidence base on screening performance across populations.
• Continued reliance on research rather than universal screening, at least for now.

Why it matters

Prostate cancer outcomes can vary by ethnicity, and screening that uses inaccurate tests can lead to avoidable follow-up procedures, anxiety, and overdiagnosis. By expanding a controlled study, policymakers appear to be seeking more reliable answers—especially about whether (and how) screening could work better than existing methods for groups that have historically been underrepresented in clinical evidence.

In the meantime, the key point is that the program is an effort to generate data through a trial, not an immediate endorsement of broad screening for all men.